Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
AVGR

AVGR - Avangardco Investments Public Ltd Stock Price, Fair Value and News

$0.470.00 (0.00%)
Market Closed

AVGR Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

AVGR Price Action

AVGR RSI Chart

AVGR Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

AVGR Valuation

AVGR Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

AVGR Fundamentals

AVGR Revenue

AVGR Earnings

AVGR Profitability

AVGR Investor Care

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20247.6M7.4M7.3M0
20238.3M8.2M7.7M7.7M
20229.5M8.8M8.7M8.3M
20219.1M10.4M10.5M10.1M
20209.6M8.7M8.6M8.8M
20197.9M8.2M8.6M9.1M
20188.3M7.9M7.8M7.9M
201718.2M15.9M12.7M9.9M
201613.2M14.8M17.4M19.2M
201511.2M10.8M10.9M10.7M
201412.5M12.1M11.7M11.2M
201300013.0M
Get all data in R, Python etc through our Historical Stock Data APIs

About Avangardco Investments Public Ltd

AVGR
Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral artery disease (PAD) in the United States and internationally. It develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. The company's lumivascular products comprise Lightbox imaging consoles, as well as the Ocelot family of catheters, including Ocelot and Tigereye, which are designed to allow physicians to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients. In addition, its chronic total occlusion (CTO)-crossing catheters, Wildcat and Kittycat 2, which employs a proprietary design that uses a rotational spinning technique allowing the physician to switch between passive and active modes when navigating across a CTO. Further, the company develops IMAGE-BTK for the treatment of PAD lesions below-the-knee. It markets and sells its products to interventional cardiologists, vascular surgeons, and interventional radiologists. The company was incorporated in 2007 and is headquartered in Redwood City, California.
 CEO
 WEBSITEhttps://avinger.com
 SECTORHealthcare
 INDUSTRYMedical Instruments & Supplies
 EMPLOYEES71